A Message from FARE CEO Dr. Jim Baker
We were sad to learn that Dr. Jim Baker will be resigning his position as CEO of FARE. This is the perfect time to look back on all that has been accomplished during his tenure and to pledge to help carry on the organization’s life-saving work. As just one example, FARE was one of the lead sponsors of the landmark research study which led to the development of new early feeding guidelines issued by the National Institute of Allergy & Infectious Diseases.
A Message from FARE CEO Dr. Jim Baker
Dear Friends of FARE,
I first arrived at FARE as interim CEO and Chief Medical Officer early in the summer of 2014, having been asked to temporarily lead the organization through a transition period. I expected to stay less than six months, but have been at the helm of this remarkable organization for what will soon be four years. The time has now come when I feel comfortable stepping aside as FARE moves onto a new chapter, and today I am announcing my resignation.
FARE’s Board of Directors is launching a comprehensive search for my successor, and I plan to remain here during the search to aid with this transition. You can learn more in FARE’s press release.
I have a tremendous amount of pride in what we have accomplished together during my time here, and hope you will indulge me as I reflect on some of these major milestones.
As you may recall, we updated our mission statement shortly after I arrived to better capture our commitment to the individuals and families that we serve. The work that we have done since then — from our significant investment in research to our wide-ranging education, advocacy and awareness initiatives — have all been guided by FARE’s tenets of LIFE, HEALTH, and HOPE.
With your support, we have made remarkable progress in every facet of our mission:
- We established the FARE Clinical Network, a national collaborative of leading research and clinical care institutions that seeks to accelerate the development of drugs for patients with food allergies and improve the quality of care for those affected.
- To address gaps in research, we launched the FARE Patient Registry, which harnesses the power of patient data to advance research discoveries by collecting demographic and clinical information from volunteer patients and family members managing food allergies.
- We advocated in states across the country for legislation that improves the safety of individuals with food allergies and have seen the number of states that allow or require stock epinephrine in schools climb to 49 and the number of states with entity legislation rise to 31.
- We ramped up our advocacy efforts related to epinephrine affordability, airline accommodations and food labeling.
- To attract more gifted scientists to the field of food allergy, we created the FARE Investigator in Food Allergy Awards, which to date have granted $3.6 million to early and mid-career investigators working on innovative studies that might not otherwise receive funding.
- We raised the profile of food allergy and created awareness and empathy for children with food allergies through the launch of the Teal Pumpkin Project®, a national campaign that is now widely recognized coast to coast.
- In the area of prevention, we saw exciting results published in the LEAP and LEAP-On studies, which led to the development of new early feeding guidelines issued by the National Institute of Allergy & Infectious Diseases. FARE was one of the lead sponsors of this landmark research study that will have a major impact on future generations.
- We educated countless parents, teens and adults managing food allergies through regular webinars, our world-class conferences and Teen Summits.
I am incredibly proud of what we have been able to achieve in these last few years. Whether you are a donor, a volunteer, a sponsor or otherwise a member of the FARE community, I am deeply appreciative for your continued support.
While we have made a significant impact on the lives of millions of Americans, there is still much more work ahead. With a strong, dynamic team in place and a strong foundation, I am confident about the direction that FARE is heading. All of us here are unwavering in our commitment to improving the quality of life and the health of individuals with food allergies, while providing hope through the promise of new treatments.
James R. Baker Jr., MD